These mutations result in various clinical phenotypes, including type 2 diabetes mellitus (T2D), immunodeficiency, tubulo-interstitial kidney disease and neutropenia (for mutations in SEC61A1). This evidence concerns the gene SEC61A1 and type 2 diabetes mellitus.